Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sana Biotechnology
Thumbnail
October 05, 2021

Biotech listings show signs of a slowdown

2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.

Thumbnail
June 03, 2021

Biopharma and venture capital: a deep dive

Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.

Article image
Vantage logo
May 26, 2021

Secretive Lyell pulls back the curtain

Article image
Vantage logo
April 08, 2021

The flotation window stays open, for now

The first quarter of 2021 sets a new record, but the tide might be starting to turn.

Article image
Vantage logo
January 13, 2021

After a big year, biotech flotations have much to do

Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.

Article image
Vantage logo
January 07, 2021

Covid or not, venture financing breaks records

Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.

Article image
Vantage logo
August 17, 2020

With a following wind JW looks to go public

The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.

Article image
Vantage logo
July 10, 2020

Venture investors: biotech's preppers?

A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

July 18, 2022

Medtech - Going steady

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.